Intravenous aNP-mRNA<sub>IL-2</sub> administration in mice led to sustained IL-2 production in the spleen and lymph nodes, significantly inhibiting tumor growth in B16F10 melanoma and MC38 colon cancer models. Here, IL2 is linked to malignant colon neoplasm.